Title
Survival outcomes and response rates among patients with recurrent or metastatic head and neck squamous cell carcinoma
Authors
Soumya Allurkar1,*, Hiren Hansraj Patadiya2, Himani Marmat3, Debapriya Kundu4, Satinder Pal Singh Tulsi5 & Satya Prakash Gupta5
Affiliation
1Department Oral and Maxillofacial Surgery, PMNM Dental College and Hospital, Bagalkot, Karnataka, India; 2Dental Practice, My Dental Southbridge, 305 Main st Southbridge, MA, USA-01550; 3Department of Medicine, Government Medical College, Ratlam, Madhya Pradesh, India; 4Intern, Kalinga Institute of Dental Sciences, KIIT Deemed to be University, Patia - 751024, Odisha, India; 5Department of Oral and Maxillofacial Surgery, Chandra Dental College, Safedabad, Barabanki, Lucknow, Uttar Pradesh, India; *Corresponding author
Soumya Allurkar - E - mail: soumya.allurkar@gmail.com
Hiren Hansraj Patadiya - E - mail: drhirendmd@gmail.com
Himani Marmat - E - mail: himani.marmat@gmail.com
Debapriya Kundu - E - mail: dkundu541@gmail.com
Satinder Pal Singh Tulsi - E - mail: spstulsi@gmail.com
Satya Prakash Gupta - E - mail: satyagupta7@gmail.com
Article Type
Research Article
Date
Received January 1, 2025; Revised January 31, 2025; Accepted January 31, 2025, Published January 31, 2025
Abstract
Evaluation of survival outcomes and response rates among patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) treated with checkpoint inhibitors is of interest. Data regarding overall survival (OS), progression free survival (PFS), response rate, PD-L1 combined positive score (CPS) was retrieved. A total of 412 patients with histo-pathologically confirmed recurrent or metastatic HNSCC who received checkpoint inhibitor (CPI) treatment were ultimately included as members of the cohort. In our study median OS was 13.1 months. Median PFS was 4.1 months. The estimated 1-year OS was 53.9% while estimated 1-year PFS was 9.7%. Our findings support the use of CPI therapies for first- or second-line treatment of recurrent or metastatic HNSCC.
Keywords
Checkpoint inhibitors, head and neck squamous cell carcinoma (HNSCC), recurrent, metastatic
Citation
Allurkar et al. Bioinformation 21(1): 44-47 (2025)
Edited by
Vini Mehta
ISSN
0973-2063
Publisher
License
This is an Open Access article which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. This is distributed under the terms of the Creative Commons Attribution License.
